FOXO4-DRI Key Research Facts Full name: FOXO4 D-Retro-Inverso peptide (FOXO4-DRI) Classification: Cell-penetrating senolytic peptide FOXO4/p53 protein-protein interaction inhibitor Design: D-retro-inverso isoform of FOXO4s p53-binding domain reversed sequence with all D-amino acids Binding target: p53 transactivation domain 2 (TAD2) displaces FOXO4 from the FOXO4-p53 complex Mechanism: FOXO4-DRI binds p53 TAD2 p53 nuclear exclusion p53 mitochondrial translocation BAX activation caspase-3 cleavage senescent cell-selective apoptosis Selectivity basis: FOXO4 is upregulated in senescent cells but expressed at low levels in most non-senescent adult cells selectivity is mechanistically conferred D-amino acid advantage: Proteolytic stability resistant to intracellular peptidases that would rapidly degrade equivalent L-amino acid sequences Structural characterisation: NMR structural models of FOXO4-DRI/p53TAD2 complex resolved (Nature Communications, 2025) confirms disordered-to-ordered transition upon binding Research cell types studied: IMR90 fibroblasts, TM3 Leydig cells, endothelial cells, chondrocytes, keloid fibroblasts, HCT116 cancer cells In vitro working concentration: 25 M used in multiple published studies for senescent cell apoptosis induction What Does FOXO4-DRI Do in Research
Incompatible Ingredients (to be separated) To avoid irritation or reduced efficacy, it's generally advised to separate GHK-Cu from: High Concentrations of L-Ascorbic Acid (Vitamin C): The low pH of L-ascorbic acid can destabilize GHK-Cu, reducing its effectiveness
The Association of Inflammation with Premenstrual Symptoms
This advanced delivery method helps neutralize free radicals, bolster your immune system, and promote overall vitality.
The Department of Health and Human Services later referred the company to the Department of Justice after it announced the launch of a $49 version of Novo Nordisks Wegovy pill
First, the biology and the evidence, because the personal experience means nothing without the context that frames it
